Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
148P Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Teiji Kuzuya, T. Yamashita, T. Takehara, Hiroshi Aikata, Naoya Kato, Yoichi Hiasa, Shinichiro Nakamura, N. Morimoto, M. Moriguchi, Masafumi Ikeda, Jun‐ichiro Inoue, Joji Tani, Yoshiyuki Ueno, Kazuaki Chayama, Ryosuke Tateishi, Y. Kawamura, Junji Furuse, Masatoshi Kudo, Kazuhiro Yamamoto, Norihiro Kokudo (2023). 148P Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR). , 34, DOI: https://doi.org/10.1016/j.annonc.2023.10.283.
Article18 days agoArtificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts
Naoshi Nishida, Makoto Yamakawa, Tsuyoshi Shiina, Yoshito Mekada, Mutsumi Nishida, Naoya Sakamoto, Takashi Nishimura, Hiroko Iijima, Toshiko Hirai, Ken Takahashi, Masaya Sato, Ryosuke Tateishi, Masahiro Ogawa, Hideaki Mori, Masayuki Kitano, Hidenori Toyoda, Chikara Ogawa, Masatoshi Kudo (2022). Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts. , 57(4), DOI: https://doi.org/10.1007/s00535-022-01849-9.
Article18 days agoReal-world data in 1000 patients with unresectable hepatocellular carcinoma (HCC) treated with systemic therapy: Patient background in PRISM study.
Masafumi Ikeda, Shinji Itoh, Ryosuke Tateishi, Tatsuya Yamashita, Takuji Okusaka, Naoya Kato, Junji Furuse, Masatoshi Kudo (2023). Real-world data in 1000 patients with unresectable hepatocellular carcinoma (HCC) treated with systemic therapy: Patient background in PRISM study.. , 41(4_suppl), DOI: https://doi.org/10.1200/jco.2023.41.4_suppl.566.
Article18 days agoCurrent status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL)
Kazuya Okushin, Ryosuke Tateishi, Arata Takahashi, Koji Uchino, Ryo Nakagomi, T. Nakatsuka, Tatsuya Minami, Masaya Sato, Mitsuhiro Fujishiro, Kiyoshi Hasegawa, Yuichiro Eguchi, Tatsuya Kanto, Shoji Kubo, Hitoshi Yoshiji, Hiroaki Miyata, Namiki Izumi, Masatoshi Kudo, Kazuhiko Koike (2022). Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). , 57(8), DOI: https://doi.org/10.1007/s00535-022-01893-5.
Article18 days agoResponse Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)
Masatoshi Kudo, Masafumi Ikeda, Kazuomi Ueshima, Michiie Sakamoto, Shuichiro Shiina, Ryosuke Tateishi, Kazuhiro Nouso, Kiyoshi Hasegawa, Junji Furuse, Shiro Miyayama, Takamichi Murakami, Tatsuya Yamashita, Norihiro Kokudo (2022). Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version). , 52(4), DOI: https://doi.org/10.1111/hepr.13746.
Article18 days ago